Dr.
A Conversation with Helen Kuo
October 18, 2021
We are pleased to introduce our colleague Hui-Hsuan (Helen) Kuo, a Ph.D. Candidate in the Department of Pharmacology, who is being mentored by our Director Olivier Elemento, Ph.D. and our Ex Vivo Models Director M. Laura Martin, Ph.D.
We hope you enjoy learning more about her research interests and background!
Question: Can you please tell me about your work as a Ph.D. candidate in the Department of Pharmacology?
Fall 2021 EIPM Newsletter
October 5, 2021
October 2021
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our third quarterly newsletter of 2021, we hope you enjoy learning more about the important progress we’ve made since June.
A Conversation with Dr. Jason G. Mezey
September 30, 2021
We are pleased to introduce our newest EIPM Member, Dr. Jason G. Mezey.
Dr. Jason Mezey is a Principal Investigator in the Cornell University Department of Biological Statistics and Computational Biology, and a new Member of the Englander Institute for Precision Medicine.
We hope you enjoy learning more about his research interests and background.
Question: Please provide a brief bio and overview of your work.
Antibody-Producing B Cells May be “Predestined” for their Fates
September 23, 2021
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
The study, published Sept. 23 in Nature Immunology, combined computational analyses with advanced molecular biology and genomic techniques to identify a protein called Oct2 as the key determinant of the B-cell humoral immune response.
Scientists Find a New Way to Reverse Immune Suppression in Tumors
September 20, 2021
Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.
Artificial intelligence in cancer research, diagnosis & therapy
September 20, 2021
“Artificial intelligence in cancer research, diagnosis and therapy,” a Viewpoint article from Nature Reviews Cancer, September 17, 2021.
In this Viewpoint article, Nature Reviews Cancer asked four experts for their opinions on how we can begin to implement artificial intelligence while ensuring standards are maintained so as transform cancer diagnosis and the prognosis and treatment of patients with cancer and to drive biological discovery.
An Ambitious New Plan to Change Medicine
September 15, 2021
Medicine is at a watershed moment: decades of technological advances have revealed unprecedented insights into human biology and how various physiological, genetic and lifestyle factors shape health. These findings have laid the groundwork for enduring change in medicine—an opportunity Weill Cornell Medicine is seizing with its June 17 launch of We’re Changing Medicine, a campaign to raise $1.5 billion for an expansive vision of medicine that will make a global impact.
September 2021 EIPM Director's Memo
September 7, 2021
Dear Members of the Englander Institute,
I’m very proud of our work over the past month, including enviable news media coverage in publications like The New York Times, the awards and grants we’ve earned, and research published in high-profile journals like The New England Journal of Medicine.
The Future? Mixed-reality headsets in I.C.U.s
August 30, 2021
Meet you in the metaverse, maybe
Facebook’s virtual reality service Horizon Workrooms, announced this month, will allow users to don a VR headset, create an avatar and sit among colleagues in computer-generated corporate settings. It’s not the only company betting on enterprise VR.